Sensei Biotherapeutics Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

Die Gewinne von Sensei Biotherapeutics werden voraussichtlich zurückgehen um 0.1% pro Jahr. Der Gewinn je Aktie wird voraussichtlich um 58.3% pro Jahr steigen.

Wichtige Informationen

-0.1%

Wachstumsrate der Gewinne

58.34%

EPS-Wachstumsrate

Biotechs Gewinnwachstum	25.2%
Wachstumsrate der Einnahmen	n/a
Zukünftige Eigenkapitalrendite	-239.94%
Analystenabdeckung	Low
Zuletzt aktualisiert	22 May 2026

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Analyseartikel • Nov 03

Is Sensei Biotherapeutics (NASDAQ:SNSE) In A Good Position To Deliver On Growth Plans?

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...

Analyseartikel • Jul 02

We Think Sensei Biotherapeutics (NASDAQ:SNSE) Needs To Drive Business Growth Carefully

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...

Analyseartikel • Mar 14

Here's Why We're Watching Sensei Biotherapeutics' (NASDAQ:SNSE) Cash Burn Situation

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...

Analyseartikel • Aug 14

We're Hopeful That Sensei Biotherapeutics (NASDAQ:SNSE) Will Use Its Cash Wisely

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...

Seeking Alpha • Aug 09

Sensei Biotherapeutics GAAP EPS of -$0.34 beats by $0.06

Sensei Biotherapeutics press release (NASDAQ:SNSE): Q2 GAAP EPS of -$0.34 beats by $0.06. Cash, cash equivalents and marketable securities were $123.7 million as of June 30, 2022, as compared to $147.6 million as of December 31, 2021. Sensei expects its current cash balance to fund operations into the first quarter of 2025.

Analyseartikel • Apr 18

Here's Why We're Watching Sensei Biotherapeutics' (NASDAQ:SNSE) Cash Burn Situation

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

Analyseartikel • Nov 16

Sensei Biotherapeutics (NASDAQ:SNSE) Is In A Good Position To Deliver On Growth Plans

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Gewinn- und Umsatzwachstumsprognosen

NasdaqCM:SNSE - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2028	N/A	-153	N/A	N/A	1
12/31/2027	N/A	-125	N/A	N/A	1
12/31/2026	N/A	-242	N/A	N/A	1
3/31/2026	N/A	-184	-24	-24	N/A
12/31/2025	N/A	-21	-20	-20	N/A
9/30/2025	N/A	-24	-22	-22	N/A
6/30/2025	N/A	-27	-24	-24	N/A
3/31/2025	N/A	-29	-24	-24	N/A
12/31/2024	N/A	-30	-25	-25	N/A
9/30/2024	N/A	-30	-25	-25	N/A
6/30/2024	N/A	-30	-24	-24	N/A
3/31/2024	N/A	-32	-28	-28	N/A
12/31/2023	N/A	-34	-32	-32	N/A
9/30/2023	N/A	-39	-36	-35	N/A
6/30/2023	N/A	-45	-38	-38	N/A
3/31/2023	N/A	-46	-40	-40	N/A
12/31/2022	N/A	-49	-39	-39	N/A
9/30/2022	N/A	-46	-38	-37	N/A
6/30/2022	N/A	-42	-37	-36	N/A
3/31/2022	N/A	-41	-32	-30	N/A
12/31/2021	N/A	-37	-32	-30	N/A
9/30/2021	N/A	-33	-27	-25	N/A
6/30/2021	N/A	-28	-28	-25	N/A
3/31/2021	N/A	-23	-24	-22	N/A
12/31/2020	N/A	-20	-19	-18	N/A
9/30/2020	N/A	-23	-18	-17	N/A
12/31/2019	N/A	-21	N/A	-9	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: SNSE wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: SNSE wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: SNSE wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: Die Daten reichen nicht aus, um festzustellen, ob die Einnahmen von SNSE schneller wachsen werden als der Markt von US.

Hohe Wachstumseinnahmen: SNSE wird im nächsten Jahr voraussichtlich keine Einnahmen haben.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: SNSE wird voraussichtlich in 3 Jahren unrentabel sein.

Wachstumsunternehmen entdecken

Unternehmensanalyse und Finanzdaten Status

Daten	Zuletzt aktualisiert (UTC-Zeit)
Unternehmensanalyse	2026/05/24 05:49
Aktienkurs zum Tagesende	2026/05/22 00:00
Gewinne	2026/03/31
Jährliche Einnahmen	2025/12/31

Datenquellen

Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.

Paket	Daten	Zeitrahmen	Beispiel US-Quelle ^*
Finanzdaten des Unternehmens	10 Jahre	Gewinn- und Verlustrechnung Kapitalflussrechnung Bilanz	SEC-Formular 10-K SEC-Formular 10-Q
Konsensschätzungen der Analysten	+3 Jahre	Finanzielle Vorausschau Kursziele der Analysten	Analysten Research Berichte Blue Matrix
Marktpreise	30 Jahre	Aktienkurse Dividenden, Splits und Aktionen	ICE-Marktdaten SEC-Formular S-1
Eigentümerschaft	10 Jahre	Top-Aktionäre Insiderhandel	SEC-Formular 4 SEC-Formular 13D
Verwaltung	10 Jahre	Das Führungsteam Direktorium	SEC-Formular 10-K SEC-Formular DEF 14A
Wichtige Entwicklungen	10 Jahre	Ankündigungen des Unternehmens	SEC-Formular 8-K

* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.

Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.

Analysemodell und Schneeflocke

Einzelheiten zu dem Analysemodell, mit dem dieser Bericht erstellt wurde, finden Sie auf unserer Github-Seite. Außerdem bieten wir Leitfäden zur Verwendung unserer Berichte und Tutorials auf YouTube an.

Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.

Metriken für Industrie und Sektor

Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.

Analysten-Quellen

Sensei Biotherapeutics, Inc. wird von 6 Analysten beobachtet. 1 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.

Analyst	Einrichtung
Zhiqiang Shu	Berenberg
Geoffrey Meacham	Citigroup Inc
Edward White	H.C. Wainwright & Co.

Sensei Biotherapeutics Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Price target increased by 17% to US$4.50

Price target decreased by 8.8% to US$3.88

Price target decreased by 13% to US$4.33

Price target decreased to US$8.00

Price target decreased to US$11.00

Recent updates

New major risk - Revenue and earnings growth

New major risk - Negative shareholders equity

Sensei Biotherapeutics Doses First Patient in Phase 1b/2 Trial of PIKTOR in HR+/HER2- Advanced Breast Cancer

Sensei Biotherapeutics, Inc., Annual General Meeting, Jun 10, 2026

Sensei Biotherapeutics, Inc. announced that it expects to receive $199.994578 million in funding from The B Group, Inc., Balyasny Asset Management L.P., Columbia Threadneedle Investments NA, Cormorant Asset Management, LP, Fairmount Co, Logos Capital LLC, Vivo Capital LLC and other investors.

Sensei Biotherapeutics, Inc. Announces Directorate Appointments, Effective February 13, 2026

New major risk - Market cap size

Sensei Biotherapeutics Reports New Clinical Results Highlighting Durable Progression Free Survival Data for Solnerstotug in Pd-(L)1 Resistant Tumors At the Esmo Congress 2025

New major risk - Share price stability

Sensei Biotherapeutics to Present Clinical Data from the Phase 1 Dose Expansion Cohort of Solnerstotug At the European Society for Medical Oncology Congress 2025

Sensei Biotherapeutics Regains Compliance with Nasdaq Listing Rule 5550(a)(2)

Price target increased by 17% to US$4.50

Sensei Biotherapeutics, Inc., Annual General Meeting, May 21, 2025

Insufficient new directors

New minor risk - Share price stability

Sensei Biotherapeutics, Inc. Reports Favorable Preliminary Dose Expansion Data for Solnerstotug in PD-(L)1 Resistant Tumors

Price target decreased by 8.8% to US$3.88

Nasdaq Grants Second Extension Till July 7, 2025 to Sensei Biotherapeutics to Regain Compliance with Minimum Bid Price Requirement

Sensei Biotherapeutics, Inc. to Close its Research Site in Rockville, Maryland and Reduce its Workforce by Approximately 46%

Sensei Biotherapeutics Receives Letter from Nasdaq Regarding Non-Compliance with Nasdaq Listing Rule 5450(a)(1)

Price target decreased by 13% to US$4.33

Sensei Biotherapeutics, Inc., Annual General Meeting, Jun 11, 2024

Sensei Biotherapeutics to Present Topline Clinical Data from the SNS-101 Phase I Dose Escalation Study at the 2024 ASCO Annual Meeting

New minor risk - Share price stability

Sensei Biotherapeutics, Inc. Announces Management Changes

High number of new directors

Newtyn Partners, LP and Newtyn TE Partners, LP, managed by Newtyn Management, LLC cancelled the acquisition of remaining 93.48% stake in Sensei Biotherapeutics, Inc. (NasdaqGM:SNSE).

Sensei Biotherapeutics, Inc. Appoints Stephanie Krebs, Ms, Mba, as Chief Business Officer

Is Sensei Biotherapeutics (NASDAQ:SNSE) In A Good Position To Deliver On Growth Plans?

Sensei Biotherapeutics, Inc. to Present Initial Clinical Data from Dose Escalation Trial of SNS 101 At 2023 SITC Annual Meeting

Sensei Biotherapeutics Receives Non-Compliance Notice from Nasdaq

Sensei Biotherapeutics Announces Initiation of Combination Arm for Phase 1/2 Clinical Study of SNS-101 with Regeneron's Libtayo

Sensei Biotherapeutics, Inc. Presents New Preclinical Data Reinforcing SNS-101 Pharmacokinetic Profile, Safety Characteristics and Mechanism of Action

We Think Sensei Biotherapeutics (NASDAQ:SNSE) Needs To Drive Business Growth Carefully

Sensei Biotherapeutics, Inc., Annual General Meeting, Jul 10, 2023

Sensei Biotherapeutics, Inc. Announces First Patient Dosed in Phase 1/2 Clinical Trial of SNS-101

Here's Why We're Watching Sensei Biotherapeutics' (NASDAQ:SNSE) Cash Burn Situation

High number of new directors

eSensei Biotherapeutics, Inc. Announces Reduction of Total Workforce

Sensei Biotherapeutics, Inc. Announces Executive Changes

High number of new and inexperienced directors

Sensei Biotherapeutics, Inc. Presents Preclinical Data at the 37th Society for Immunotherapy of Cancer (SITC) Annual Meeting

Apeiron Investment Sends a Letter to Sensei Biotherapeutics

Sensei Biotherapeutics, Inc. Presents Preclinical Data for SNS-101, a Conditionally Active VISTA-blocking Antibody, at the Sixth Annual CRI-ENCI-AACR International Cancer Immunotherapy Conference: Translating Science into Survival

Sensei Biotherapeutics, Inc. Announces New Preclinical Data Demonstrating Favorable Pharmacokinetic and Immunologic Effects of SNS-101, A Ph-Selective Vista-Blocking Antibody

We're Hopeful That Sensei Biotherapeutics (NASDAQ:SNSE) Will Use Its Cash Wisely

Sensei Biotherapeutics GAAP EPS of -$0.34 beats by $0.06

Sensei Biotherapeutics, Inc.(NasdaqGM:SNSE) dropped from Russell 2500 Value Index

Sensei Biotherapeutics Appoints Patrick Gallagher, MBA, MPH, as Chief Business Officer

Price target decreased to US$8.00

High number of new and inexperienced directors

Here's Why We're Watching Sensei Biotherapeutics' (NASDAQ:SNSE) Cash Burn Situation

Price target decreased to US$11.00

Chairman of The Board recently bought US$80k worth of stock

Chairman of The Board recently bought US$136k worth of stock

Chairman of The Board recently bought US$53k worth of stock

Independent Director recently bought US$57k worth of stock

Independent Director recently bought US$250k worth of stock

Sensei Biotherapeutics (NASDAQ:SNSE) Is In A Good Position To Deliver On Growth Plans

Chief Scientific Officer recently sold US$568k worth of stock

Sensei Biotherapeutics, Inc.(NasdaqGM:SNSE) dropped from Russell 3000E Growth Index

Sensei Biotherapeutics, Inc. Announces New Clinical Data from the Ongoing Phase 1/2 Combination Trial of SNS-301 in Patients with Squamous Cell Carcinoma of the Head and Neck

Sensei Biotherapeutics, Inc. announced that it has received $34.5 million in funding from a group of investors

Independent Director recently bought US$143k worth of stock

Independent Director recently bought US$233k worth of stock

Sensei Biotherapeutics Appoints Deneen Vojta to the Board of Directors

Sensei Biotherapeutics, Inc. has completed an IPO in the amount of $133.000988 million.

Gewinn- und Umsatzwachstumsprognosen

Analystenprognosen zum zukünftigen Wachstum

Wachstumsprognosen für den Gewinn je Aktie